NASDAQ:RDHL Redhill Biopharma (RDHL) Stock Price, News & Analysis $0.54 0.00 (-0.39%) As of 10:47 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsInsider TradesNews and TrendsOwnershipSEC Filings About Redhill Biopharma Stock (NASDAQ:RDHL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Redhill Biopharma alerts:Sign Up Key Stats Today's Range$0.54▼$0.5650-Day Range$0.54▼$0.9052-Week Range$0.52▼$2.79Volume27,957 shsAverage Volume855,440 shsMarket Capitalization$3.29 millionP/E Ratio0.00Dividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and certain infectious diseases. The company was founded in Israel and conducted operations primarily in the United States, where it pursued regulatory approval, commercialization and clinical development activities. RedHill’s principal commercial product was Talicia, an oral combination of rifabutin, amoxicillin and omeprazole approved by the U.S. Food and Drug Administration to treat Helicobacter pylori infection in adults. The company also commercialized Aemcolo, an oral, locally acting antibiotic formulation based on rifamycin for certain cases of travelers’ diarrhea. Its development pipeline included investigational treatments for gastrointestinal disorders, infections and other conditions, although not all of these programs reached approval. RedHill was led for several years by Mark L. Sirgo, who served as president and chief executive officer. The company’s shares traded on the Nasdaq Capital Market under the symbol RDHL; however, RedHill subsequently faced significant operating and financial challenges, and its public-market listing and business activities were materially reduced. Information about its current operations and leadership may therefore be limited.AI Generated. May Contain Errors. Read More Redhill Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreRDHL MarketRank™: Redhill Biopharma scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingRedhill Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageRedhill Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Redhill Biopharma's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Redhill Biopharma is 0.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.99.Price to Earnings Ratio vs. SectorThe P/E ratio of Redhill Biopharma is 0.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.06.Price to Book Value per Share RatioRedhill Biopharma has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.15% of the float of Redhill Biopharma has been sold short.Short Interest Ratio / Days to CoverRedhill Biopharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Redhill Biopharma has recently decreased by 43.07%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRedhill Biopharma does not currently pay a dividend.Dividend GrowthRedhill Biopharma does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest4 people have searched for RDHL on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Redhill Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders6.81% of the stock of Redhill Biopharma is held by insiders.Percentage Held by Institutions7.20% of the stock of Redhill Biopharma is held by institutions.Read more about Redhill Biopharma's insider trading history. Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Redhill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RDHL Stock News HeadlinesNovartis (NYSE:NVS) versus Redhill Biopharma (NASDAQ:RDHL) Head-To-Head ReviewSeptember 16, 2026 | americanbankingnews.comRedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?September 10, 2026 | finance.yahoo.comI went to a party with Elon...Josh Baylin, a former Bloomberg tech reporter and ex-SAC Capital analyst, has spent weeks building a paper trail pointing to a new Elon-linked AI device. The FCC recently granted a key approval tied to the project, adding another data point to Baylin's research. His full report, along with the name and ticker of the stock he's watching, is available free.September 24 at 1:00 AM | Stansberry Research (Ad)Redhill Biopharma stock doubles in one session — here's whySeptember 1, 2026 | msn.comRedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®September 1, 2026 | markets.businessinsider.comRedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®September 1, 2026 | prnewswire.comRedHill Biopharma Stock Surges 64% Over Deal To Divest Talicia BusinessAugust 31, 2026 | rttnews.comRedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth OpportunitiesAugust 31, 2026 | prnewswire.comSee More Headlines RDHL Stock Analysis - Frequently Asked Questions How have RDHL shares performed this year? Redhill Biopharma's stock was trading at $1.03 at the start of the year. Since then, RDHL stock has decreased by 47.3% and is now trading at $0.5431. How were Redhill Biopharma's earnings last quarter? Redhill Biopharma Ltd. (NASDAQ:RDHL) posted its earnings results on Tuesday, November, 30th. The biotechnology company reported ($500.00) earnings per share for the quarter, missing analysts' consensus estimates of ($480.00) by $20.00. The biotechnology company earned $21.61 million during the quarter, compared to analysts' expectations of $23.41 million. When did Redhill Biopharma's stock split? Redhill Biopharma shares reverse split on Tuesday, August 20th 2024.The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Redhill Biopharma? Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Redhill Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Redhill Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), AbbVie (ABBV). Company Calendar Last Earnings11/30/2021Today9/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (7m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 RDHL's financial health is in the Yellow zone, according to TradeSmith. RDHL has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RDHL Previous SymbolASX:RDH CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Fax972-3541-3144Employees210Year Founded2009Profitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio0.00 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick Ratio0.34 Sales & Book Value Annual Sales$290 thousand Price / Sales11.59 Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book0.67Miscellaneous Outstanding Shares6,080,000Free Float5,667,000Market Cap$3.36 million OptionableNo Data Beta4.96 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:RDHL) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe Pentagon Has 120 Days to Solve This Critical Mineral ProblemChina controls roughly 80% of the world's tungsten supply, and new Pentagon sourcing restrictions take effect ...The Tomorrow Investor | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
